Latest news and articles about obesity from NEX English
Weight loss injections are gaining popularity, but their effectiveness varies among individuals. This discrepancy raises important questions for researchers and health professionals in the fields of nutrition and health.
Questions are rising about the link between sugar consumption and cancer. While sugar is not a direct cause, research indicates its indirect effects on risk factors.
A recent study indicates that individuals with specific genetic mutations can achieve greater weight loss when using medications like Wegovy and Mounjaro. These findings may explain the significant differences in drug efficacy among individuals.
Recent studies indicate a continuous increase in birth weights across various communities, raising concerns about children's health. This trend necessitates immediate action from stakeholders to ensure the well-being of future generations.
Daily habits can negatively impact weight, with simple behaviors leading to unnoticed weight gain. This article explores seven common habits contributing to this issue.
The United Arab Emirates has announced the acceleration of the development of new weight loss pills, raising questions about their cost and availability for patients. This announcement comes at a time when obesity rates are rising in the region.
The weight loss drug market has experienced significant transformations in recent years, with pills and injections increasingly competing to meet consumer needs. This competition reflects changing consumer preferences regarding cost and convenience.
Dr. Sanjay Bujrag, a cardiologist, warns that prolonged sitting can double the risk of heart disease. He emphasizes that a lack of movement is a major factor negatively impacting heart health.
Eli Lilly has announced that its new drug 'Foundio' has received approval from the US Food and Drug Administration, paving the way for strong competition in the oral obesity medication market. This development comes as companies strive to provide effective solutions to the global obesity crisis.
Eli Lilly has announced the launch of a new weight loss medication called <strong>Foundayo</strong>, which can be taken once daily at any time. This drug is considered a major competitor to <strong>Wegovy</strong> in the weight loss market.
Novo Nordisk's CEO revealed that the weight loss drug industry has only reached <strong>15%</strong> of potential customers, indicating significant untapped opportunities. This statement comes amid rising global demand for weight loss medications.
Recent studies indicate a significant rise in liver transplant patients, increasingly linked to obesity and diabetes rather than viral hepatitis. This trend calls for preventive measures before liver-related diseases worsen.
Research indicates that obesity is a complex issue influenced not only by food quality but also by behaviors and attitudes towards eating. Simply urging people to eat healthily has not led to a decrease in obesity rates.
The United Arab Emirates has announced the launch of new daily weight loss pills, which will be available in markets starting next month. This initiative is part of the country's efforts to combat obesity and promote public health.
The UAE's health authority has approved a new oral treatment for obesity, set to be available to the public starting May 2024. This initiative is part of the country's efforts to combat obesity and improve the health of its citizens and residents.
Recent statistics indicate that the obesity prevalence rate among Saudi residents aged over 15 years has reached 23.1%. This figure highlights increasing health challenges facing the Saudi community.
The Emirates Drug Authority has approved the innovative oral treatment Orforglipron 'Fondaio™' to combat obesity, making the UAE the second country worldwide to grant marketing approval for this drug produced by Eli Lilly.
A recent study has uncovered a strong correlation between obesity and an increased risk of various types of cancer, highlighting the importance of addressing this global health issue. The findings indicate that individuals with obesity are more susceptible to cancers such as breast and colon cancer.
A new weight loss pill has received approval from the U.S. Food and Drug Administration, opening new avenues in the fight against obesity. This pill represents a significant step in obesity treatments, as a large percentage of the population suffers from weight gain.
The U.S. Food and Drug Administration (FDA) has granted emergency approval for a new oral medication from Eli Lilly, making it the second daily medication available for obesity treatment. This approval is a significant step in addressing health issues related to weight.
Intermittent fasting has gained popularity as a solution to obesity, but it is not a miracle. Its success relies on calorie reduction and may not suit everyone.
The U.S. Food and Drug Administration has approved a new weight loss medication from Eli Lilly, marking a significant step in the fight against obesity affecting millions of Americans. The drug promises high effectiveness in reducing weight and improving overall health.
A recent study highlights that weight loss is a key factor in cancer prevention. Research indicates that excess weight increases the risk of various types of cancer, emphasizing the importance of maintaining a healthy weight.
A recent German study indicates that obesity significantly increases the risk of multiple types of cancer, necessitating effective preventive measures such as weight loss. The findings highlight the importance of health awareness in communities.
Potatoes are a beloved food in many cultures, but excessive consumption can negatively impact diets. Studies indicate that high potato intake may lead to weight gain and other health issues.
The U.S. Food and Drug Administration (FDA) has granted fast approval for a new drug from Eli Lilly aimed at addressing obesity. This decision comes as many countries face rising obesity rates among their populations, raising significant public health concerns.
Novo Nordisk has announced new details regarding competition in the weight loss drug market following Eli Lilly's recent approval of a new obesity treatment. This comes as the obesity drug market experiences significant expansion with the introduction of new subscription models.
A new weight loss medication from <strong>Lilly</strong> has received approval from the <strong>U.S. Food and Drug Administration</strong>, paving the way for strong competition with <strong>Novo Nordisk</strong>. This development comes at a time when interest in obesity treatments is surging in the United States.
Novo Nordisk has achieved the best obesity drug launch this year with its medication Wegovy, surpassing 600,000 prescriptions. This move comes as Eli Lilly intensifies competition by introducing new pills to attract patients.
The U.S. Food and Drug Administration has approved Eli Lilly's Foundayo pill, paving the way for a new entrant in the weight loss medication market. The new pill will be available to consumers at varying prices, reflecting increasing competition among manufacturers.